Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00609154 · ClinicalTrials.gov registry record · Phase 1
Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates
A Phase 1 study, sponsored by Albert Einstein College of Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00609154: Clinical Trial Phase 1 study, sponsored by Albert Einstein College of Medicine.
NCT00609154 is a Phase 1 study that was terminated before completion, run by Albert Einstein College of Medicine. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00609154, a Phase 1 study, was terminated before completion, sponsored by Albert Einstein College of Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The gut hormone glucagon like peptide-1 (GLP-1) has been shown to have important effects on maintaining the function and health of the insulin producing beta cells. This hormone is known to increase the production rate of new insulin as well as increase the release of insulin into the blood.
Primary Outcome
Blood insulin biosynthesis rate
Interventions
- DRUG glucagon like peptide-1
- DIETARY_SUPPLEMENT glucose control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2010-08-12 |
| Est. Completion | 2014-05-13 |
| Phase | Phase 1 |
Why NCT00609154 stopped before completion
NCT00609154 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 2 interventions - of which glucagon like peptide-1 is the first listed.
NCT00609154 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00609154 about?
NCT00609154 is a clinical study titled "Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates". The gut hormone glucagon like peptide-1 (GLP-1) has been shown to have important effects on maintaining the function and health of the insulin producing beta cells. This hormone is known to increase the production rate of new insulin as well as increase the release of insulin into the blood.
What is the current status of trial NCT00609154?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2010-08-12. Estimated completion is 2014-05-13.
What interventions are being tested in trial NCT00609154?
The interventions under investigation include: glucagon like peptide-1 (DRUG), glucose control (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00609154?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00609154's enrollment target sits among peer trials
20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI